Aerosolized Dornase Alfa (DNase I) for the Treatment of Severe Respiratory Failure in COVID-19: A Randomized Controlled Trial
Aerosolized dornase alfa failed to improve hypoxia in hospitalized patients with acute COVID-19. The study was conducted during a time of heterogeneity in viral variants and vaccination status of participants. Whether dornase alfa affects the outcomes in other respiratory infections requires further study.
Authors
- M. Wallberg
- Lisa Mellhammar (ORCID: https://orcid.org/0000-0002-7623-0342)
- Magnus Rasmussen (ORCID: https://orcid.org/0000-0003-1588-5473)
- Per Åkesson
- Malin Inghammar (ORCID: https://orcid.org/0000-0003-2995-1312)
- John Walles (ORCID: https://orcid.org/0000-0002-3445-7741)
- Fredrik Månsson (ORCID: https://orcid.org/0000-0002-2802-0420)
- Adam Linder (ORCID: https://orcid.org/0000-0002-8187-7239)
- Attila Frigyesi (ORCID: https://orcid.org/0000-0002-0155-4828)
- Elin Economou Lundeberg (ORCID: https://orcid.org/0009-0006-6296-2522)
- Sara Jesperson
Institutions
- Malmö University (SE)
- Lund University (SE)
- Kristianstad University (SE)
- Skåne University Hospital (SE)
- Centralsjukhuset Kristianstad (SE)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2025-04-24
- DOI
- https://doi.org/10.1093/ofid/ofaf246
- Citations
- 7
- Primary Topic
- Respiratory Support and Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 10.63